Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

third quarter and first nine months of 2012, respectively.

Net loss in the third quarter of 2013 was $16.5 million or $0.14 per share as compared to a net loss of $43.5 million or $0.38 per share in the third quarter of 2012. Net loss in the first nine months of 2013 was $114.4 million or $0.99 per share as compared to a net loss of $118.9 million or $1.04 per share in the first nine months of 2012.

Conference Call to Discuss Third Quarter 2013 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time today, Thursday, November 7, 2013.

This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, December 9, 2013. To access the conference call, follow these instructions: Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)Passcode: 91919000 (Nektar Therapeutics is the host)In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Based On Naturally Resected tRNA Synthetases , ... subsidiary of aTyr Pharma in Hong Kong, today announced ... naturally occurring, resected human tRNA synthetases. Although tRNA ... machinery found in all organisms, human synthetases have naturally ...
... RICHMOND, Calif., June 29 Sangamo BioSciences, Inc. (Nasdaq: ... research milestone has been achieved in its Research and ... the Roche Group, for the generation of cell lines ... Sangamo,s proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. ...
Cached Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3
(Date:7/10/2014)... of Health and Human Services (HHS) has announced a ... Seidman Cancer Center totaling $4.7 million to support a ... with complex cancer. , Titled "Evidence-Conformant Oncology Care," ... UH to enhance care for adult cancer patients with ... health care utilization. , "We believe that ...
(Date:7/10/2014)... The benefits of medical imaging far outweigh the ... Right Way, with The Right Radiation Dose. However, overuse ... Mayo Clinic is leading a collaborative effort to ensure ... published online in the Journal of Patient Safety ... Joint Commission, the Intersociety Accreditation Commission, and the Centers ...
(Date:7/10/2014)... (July 10, 2014) A research review identifying the ... important first step in the process of developing evidence-based ... a new report published by Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , Based on ...
(Date:7/10/2014)... Depressed men with localized prostate cancer were more ... cancer, received less effective treatments and survived for ... not depressed, a UCLA study has found. , ... several factors such as bias against the mentally ... depressed man,s lack of investment in his general ...
(Date:7/10/2014)... prove useful in treating small cell lung cancer - the ... Cancer Research UK Manchester Institute, based at The University of ... up with experts at AstraZeneca, as part of a collaboration ... AZD3965 - on small cell lung cancer cells. , The ... also helps identify which patients are most likely to respond ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New drug active against most aggressive type of lung cancer cells 2
... privacy in the healthcare sector is an issue of ... address the various issues raised by healthcare consumers regarding ... compliance. Writing in the International Journal of ... Johnson of Dartmouth College, Hanover, New Hampshire, USA, explain ...
... of Southern California (USC) has announced a $24 million charitable ... multi-million dollar gift will support cancer research directed by renowned ... School of Medicine of USC and director of the USC ... Cancer Center. The donation to the Keck ...
... HealthDay Reporter , THURSDAY, July 15 (HealthDay News) -- ... percent watch more than the recommended two hours of television ... rest of the country," said study co-author Dr. John Oh, ... Disease Control and Prevention, working with Oregon Public Health. ...
... Cancer Research Institute (CRI) is conducting a clinical trial that ... Lymphoma, which affects the white blood cells ... or T-cell. About 85% of lymphomas are of B-cell origin, ... chronic, but they do not respond well to chemotherapy. ...
... used to treat cancer may someday help clean up environmental ... powder hidden underneath clothing. The novel radiation mechanism developed ... team of scientists in Japan also could help doctors more ... of treatments on healthy parts of the body. The ...
... DURHAM, N.C. -- A team of Duke University researchers ... the spread of malaria while protecting human and environmental ... mosquito-borne disease occurs will be supported by a $2.2 ... Health. "We,ll be performing experiments in 24 villages ...
Cached Medicine News:Health News:Insecurities plague electronic health care 2Health News:Keck School of Medicine of USC receives $24 million gift from Sumner M. Redstone 2Health News:Keck School of Medicine of USC receives $24 million gift from Sumner M. Redstone 3Health News:Too Many Tots Watching Too Much TV: Study 2Health News:Too Many Tots Watching Too Much TV: Study 3Health News:Duke and African partners to study sustainable malaria control 2
Instrument Cover for Vibratome....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
Medicine Products: